DOI: 10.1097/dad.0000000000002677 ISSN: 0193-1091

BerEP4-Negative Basal Cell Carcinoma: An Immunophenotype Not to Forget

Douglas W. Murray, Robert W. Thiel, Mariana A. Phillips, Douglas J. Grider
  • Dermatology
  • General Medicine
  • Pathology and Forensic Medicine


Basal cell carcinoma (BCC) is the most common cancer worldwide. Although not typically metastatic, BCC can be locally destructive. BerEP4 is an antibody against CD326, an epithelial cell adhesion molecule (EpCAM) that is expressed on epithelial progenitor cells and carcinomas. BerEP4 has been reported to have a 100% positive sensitivity in basal cell carcinomas, but a much lower sensitivity for a variety of other carcinomas, including clear cell renal cell carcinoma and metastatic renal cell carcinoma. A 74-year-old woman presented with a BerEP4-negative, but anti–renal cell antibody-positive BCC, and the stark clinical implications of misdiagnosis. This case stresses the importance of considering BerEP4-negative BCC, even when other abnormal features are present.

More from our Archive